肥胖人群外周血单核细胞TLR4表达变化及他汀干预作用的研究

Research on peripheral blood mononuclear cell TLR4 expression level and interference effect of Atorvastatin on obesity populations

目的探讨肥胖人群外周血toll样受体4(TLR4)表达的变化及应用他汀类药物的作用机制是否与抑制toll样受体4(TLR4)有关。方法 57例肥胖者随机分为常规对照组和阿托伐他汀干预组,阿托伐他汀干预组给予阿托伐他汀20 mg/晚,用药前及用药后1个月采血,应用流式细胞仪检测外周血单核细胞TLR4蛋白表达;应用ELISA法检测血浆TNF-α浓度。结果单核细胞TLR4蛋白与体质量及血浆TNF-α正相关。用阿托伐他汀干预1个月后,阿托伐他汀干预组外周血单核细胞TLR4蛋白及血浆TNF-α浓度均较干预前降低(P<0.05);阿托伐他汀治疗组单核细胞TLR4蛋白和血浆TNF-α低于常规对照组(P<0.05)。结论阿托伐他汀能下调肥胖人群单核细胞TLR4表达,降低血浆炎症因子水平。其抗炎作用可能与抑制单核细胞TLR4通路有关。

Objective To investigate and analysis expression level of toll-like receptor 4 （TLR4） and to investigate whether the effect of Atorvastatin in obesity populations was correlated with down-regulating toll-like receptor 4 （TLR4） expression. Methods 57 cases of obesity populations were recruited and randomly divided into normal control group and Atorvastatin treatment group. Atorvastatin treatment group was given Atorvastatin 20 mg every night additionally. Before and after 1 month treatment, the expres- sion of TLR4 protein on monocytes was assayed by flow cytometry, concentration of plasma TNF-α was measured by ELISA. Results Monocytes TLR4 expression positively correlated with body weight and levels of plasma TNF-α. After 1 month treatment, monocytes TLR4 expression and plasma TNF-α were lower in Atorvastatin treatment group than before the treatment （ P 〈 0.05 ）. Obesity populations in Atorvastatin treatment group using Atorvastatin had less TLR4 expression and lower plasma TNF-a level than those not using in normal control group （ P 〈 0.05 ）. Conclusion Atorvastatin can decrease circulation monocytes TLR4 expression and plasma inflammatory cytokine levels in obesity populations. The anti-inflammatory effect of Atorvastatin may be partially mediated by inhibiting TLR4 signaling.